For research use only. Not for therapeutic Use.
Narsoplimab (OMS 721) is a high-affinity fully human immunoglobulin gamma 4 (IgG4) monoclonal antibody that binds MASP-2 and blocks lectin pathway activation. Narsoplimab can be used in research of hematopoietic stem-cell transplantation and SARS-CoV-2[1].
Narsoplimab (100 nM; 3 h; Vero E6 cells and Vero E6 cells with SARS-CoV-2) inhibits the N protein potentiated MASP-2 deposition[1].
Narsoplimab (10 mg/kg; i.v.; WT and Masp2-/- (KO) mice) decreases percentage of lymphocytes (Lym%) and increases percentage of neutrophils (Neu%)[1].
| Catalog Number | I042220 |
| CAS Number | 2108782-45-0 |
| Purity | ≥95% |
| Reference | [1]. Gao T, et, al. Highly pathogenic coronavirus N protein aggravates inflammation by MASP-2-mediated lectin complement pathway overactivation. Signal Transduct Target Ther. 2022 Sep 14;7(1):318. |
